Notícias e Atividades da Vertex Pharmaceuticals

Vertex Pharmaceuticals é uma das ...

• Forbes Global 2000 (#553);
• Fortune 500 (#400);
• Nasdaq 100;
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

Vertex Pharmaceuticals é uma empresa listada sob o símbolo VRTX (US).

Vertex Pharmaceuticals tem presença direta em 2 países.

Eles estão dentro:

• Biotecnologia67%
• Farmacêutica33%

Fusão, aquisição e financiamento envolvendo Vertex Pharmaceuticals.

• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (publicado em 16 de abril de 2024).

Veja o organograma con seus 62 executivos principais

Biografias mais buscadas da Vertex Pharmaceuticals

• Reshma Kewalramani, Director, President and Chief Executive Officer
• Jeffrey Leiden, Executive Chairman of the Board
• Sangeeta Bhatia, Director

Criar um alerta
para seguir os movimentos de executivos da Vertex Pharmaceuticals.

Vertex Pharmaceuticals possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Vertex Pharmaceuticals

• Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis | Vertex Pharmaceuticals Newsroom
• European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis | Vertex Pharmaceuticals Newsroom
• Vertex to Announce First Quarter 2025 Financial Results on May 5th | Vertex Pharmaceuticals Newsroom
• Vertex Announces Program Updates for Type 1 Diabetes Portfolio | Vertex Pharmaceuticals Newsroom
• Videos | Vertex Pharmaceuticals Newsroom
• Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis | Vertex Pharmaceuticals Newsroom
• Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations | Vertex Pharmaceuticals Newsroom
• Vertex to Participate in Upcoming March Investor Conferences | Vertex Pharmaceuticals Newsroom
• Vertex Reports Fourth Quarter and Full Year 2024 Financial Results | Vertex Pharmaceuticals Newsroom
• Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10 | Vertex Pharmaceuticals Newsroom
• View more press releases Close

Redes sociais sobre Vertex Pharmaceuticals

• Vertex Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Vertex Pharmaceuticals na LinkedIn, Twitter e YouTube